Sunday, May 19, 2013
"Concise industry news from the US pharmaceutical industry..."
Sponsors
Platinum Sponsors
Nanopoint, Inc.
is a privately-held biotechnology company that develops and markets unique cellular imaging systems for the life sciences market.
Read More
is a privately-held biotechnology company that develops and markets unique cellular imaging systems for the life sciences market.
Read More
Gold Sponsors
Waters Corp.
For 50 years, Waters has developed innovative analytical science solutions to support customer discoveries, operations, performance, and regulatory compliance.
Read More
For 50 years, Waters has developed innovative analytical science solutions to support customer discoveries, operations, performance, and regulatory compliance.
Read More
Silver Sponsors
Platinum Sponsors
Nanopoint, Inc.
is a privately-held biotechnology company that develops and markets unique cellular imaging systems for the life sciences market.
Read More
is a privately-held biotechnology company that develops and markets unique cellular imaging systems for the life sciences market.
Read More
Gold Sponsors
Waters Corp.
For 50 years, Waters has developed innovative analytical science solutions to support customer discoveries, operations, performance, and regulatory compliance.
Read More
For 50 years, Waters has developed innovative analytical science solutions to support customer discoveries, operations, performance, and regulatory compliance.
Read More
Silver Sponsors
Blog
Spencer Green
Chairman, GDS International
Chairman, GDS International
Sales and the 'Talent Magnet'
A lot is written about being a ‘Talent Magnet’, either as a company, or as President. It’s all good practice – listen, mentor, reward, provide clear goals and career maps. Good practice for the employer, but what about the employee?26 May 2011
You need adobe flash player to view this content
Latest News
-
Top 10 Pharma Layoffs of 2010
After cutting out 7000 employees last year, BMS only just made this year’s cut with its September layoffs. The company continues to prepare for the Plavix patent cliff, as...Read more
02/17/2011 16:42
Comments -
CureFAKtor Pharmaceuticals Receives Orph...
CureFAKtor Pharmaceuticals, LLC, a privately-held biopharmaceutical company focused on the research and development of Focal Adhesion Kinase (FAK) inhibitors for cancer, today...Read more
01/19/2011 10:27
Comments -
Pharma to See Big Growth in East in 2011
According to investment international, 2011 will be a successful year for the pharmaceutical industry due to a rise in emerging markets, which is estimated to grow by 70 percent...Read more
01/05/2011 14:23
Comments -
Neovacs: Crohn's Disease Immunotherapy T...
Neovacs, a biotechnology company focused on active immunotherapy for autoimmune and inflammatory diseases and cancer, today announced the final results of its Phase I/II clinicalRead more
12/13/2010 08:50
Comments -
Aspirin Reduces Cancer Risk by 21%
British researchers revealed in an article published in The Lancet that a daily dose in the range of 75mg to 500mg of Aspirin reduced the risk of cancer by 21 percent. In most...Read more
12/07/2010 16:48
Comments -
Ian Read to Replace Jeffrey Kindler as P...
Pfizer, the world's largest pharmaceutical company has announced that CEO Jeffrey Kindler has retired, paving the way for global biopharmaceutical operations, Ian Read, as his...Read more
12/06/2010 13:49
Comments
Editor’s Choice
-
American Society of Human Genetics to Host 60th...
The world’s top scientists and clinicians in the human genetics field will gather in Washington, D.C., to present their latest research findings at the 60th Annual Meeting of...Read more -
Psychiatric drugs: a booming business
The top 25 psychiatric drugs of 2009, according to quantities of US prescriptions, have been published and the chart reveals that approximately 300 million prescriptions were...Read more -
Stereology going mainstream
Lars Peterson discusses how whole slide stereology is beginning to make an impact in the biopharmaceutical industry.Read more -
Johnson and Johnson on open innovation and diff...
Why Johnson & Johnson’s Paul Stoffels believes greater differentiation and a move toward open innovation are the answer to the industry’s woes.Read more -
Toronto's pharmaceutical biotech sector
Denis Grant helps set the stage for excellence and innovation in Toronto’s pharmaceutical biotech sector.Read more -
Pharmaceutical brand promotion
How a shifting business environment will affect brand promotion in the pharmaceutical space.Read more
Readers’ Choice
-
Breaking New Ground
Sean Harper tells NGP why he is excited about potential new treatments for osteoporosis, why animal models aren't always useful in developing drugs for humans, and why the...Read more -
Customer Centric Service: The New Rx fo...
As the industry moves from its traditional sales and marketing approach to customer centric service models, companies are seeking to better meet physicians’ need for product,...Read more -
Pharmaceutical Marketing After the Gold ...
Targeted Analytics Become Keys to a Lean, Mean Branding Machine By Mukesh Mehta, RPhRead more -
Early Phase Research – The Problem, the ...
Members of product development teams typically visit the Phase I-II world every few years. Increasingly, however, they are finding it a different world at each visit, due to a...Read more -
In with the New
When Chris Viehbacher arrived to take up the reins as CEO of sanofi-aventis, he found a company with an image problem that had forgotten how to communicate. Now he plans to...Read more -
The Enterprise Lab Notebook
Enabling multi-disciplinary virtual teams to improve R&D productivity through knowledge sharing. By Symyx Technologies, Inc.Read more
Executive Interviews
Balancing act: aligning competing strategic obj...
IMS offers insight to new commercial model and launch excellence initiatives.
Read more
REACH out for better
As the industry raises the bar once again to protect human health and the environment against chemical substances, Ali S. Faqi discusses the implications of the REACH initiative for manufacturers of chemical substances.
Read more
Below the surface
As companies continue to magnify their efforts in the realms of manufacturing, Jeffrey L. Mooney highlights the importance in utilizing sufficient surface technologies.
Read more
White Papers
Next Generation Healthcare Summit
25th - 27th October 2010
As healthcare costs continue to rise, health providers around the country feel a sharp sense of urgency in deploying information technology to lower costs, reduce medical errors, enhance outcomes, and spur efficiency in an industry known for legendary inefficiency.
Source: www.ngpharma.com© 2013 GDS Publishing Ltd. All rights reserved.